[go: up one dir, main page]

WO2007100775A3 - Methods for regulating neurotransmitter systems by inducing counteradaptations - Google Patents

Methods for regulating neurotransmitter systems by inducing counteradaptations Download PDF

Info

Publication number
WO2007100775A3
WO2007100775A3 PCT/US2007/004959 US2007004959W WO2007100775A3 WO 2007100775 A3 WO2007100775 A3 WO 2007100775A3 US 2007004959 W US2007004959 W US 2007004959W WO 2007100775 A3 WO2007100775 A3 WO 2007100775A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
regulating
neurotransmitter systems
inducing
neurotransmitter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004959
Other languages
French (fr)
Other versions
WO2007100775A2 (en
Inventor
Alexander Michalow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP07751698A priority Critical patent/EP2001495A4/en
Priority to AU2007221135A priority patent/AU2007221135A1/en
Priority to CA002643802A priority patent/CA2643802A1/en
Priority to JP2008556468A priority patent/JP2009528289A/en
Publication of WO2007100775A2 publication Critical patent/WO2007100775A2/en
Anticipated expiration legal-status Critical
Publication of WO2007100775A3 publication Critical patent/WO2007100775A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than 1/2. The methods of the present invention may be used to address a whole host of undesirable mental, neurological and physiological conditions.
PCT/US2007/004959 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations Ceased WO2007100775A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07751698A EP2001495A4 (en) 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2007221135A AU2007221135A1 (en) 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations
CA002643802A CA2643802A1 (en) 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008556468A JP2009528289A (en) 2006-02-27 2007-02-27 Methods of modulating neurotransmitter systems by inducing counter adaptation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77719006P 2006-02-27 2006-02-27
US60/777,190 2006-02-27
US85818606P 2006-11-09 2006-11-09
US60/858,186 2006-11-09

Publications (2)

Publication Number Publication Date
WO2007100775A2 WO2007100775A2 (en) 2007-09-07
WO2007100775A3 true WO2007100775A3 (en) 2008-11-27

Family

ID=38459618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004959 Ceased WO2007100775A2 (en) 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations

Country Status (5)

Country Link
EP (1) EP2001495A4 (en)
JP (1) JP2009528289A (en)
AU (1) AU2007221135A1 (en)
CA (1) CA2643802A1 (en)
WO (1) WO2007100775A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021509A2 (en) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
ES2438020T3 (en) 2005-11-10 2014-01-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of addictions and other neuropsychiatric disorders
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2168580B1 (en) * 2007-06-22 2015-12-02 Toray Industries, Inc. Remedy or preventive for schizophrenia
WO2009109001A1 (en) * 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
BR112012032076A2 (en) 2010-06-16 2016-09-13 Univ Louisiana State pharmaceutical composition and methods for treating a patient suffering from a neurodegenerative disorder and disease
CN103313601B (en) * 2010-06-29 2015-04-08 宾夕法尼亚大学理事会 Salvinorin compositions and uses thereof
US11000505B2 (en) * 2010-06-29 2021-05-11 The Trustees Of The University Of Pennsylvania Salvinorin compositions and uses thereof
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
TWI600654B (en) 2012-11-19 2017-10-01 艾姆公司 Compounds and compositions for the treatment of parasitic diseases
US20150352100A1 (en) * 2013-01-21 2015-12-10 Avant Derma Pte. Ltd. Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands
WO2014117090A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN104955483A (en) 2013-01-30 2015-09-30 法莫斯医疗公司 Treatments for depression and other diseases with a low dose agent
WO2014170351A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder
ES2856189T3 (en) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Methods and compositions for the treatment of attention deficit hyperactivity disorder, anxiety and insomnia using transdermal compositions of dexmedetomidine
KR101827980B1 (en) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 Dexmedetomidine transdermal delivery devices and methods for using the same
ES2847936T3 (en) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Methods and compositions for the transdermal delivery of a non-sedating amount of dexmedetomidine
WO2016195723A1 (en) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
CN106008487B (en) * 2015-12-31 2019-08-09 北京理工大学 A kind of stilbene derivative and preparation method thereof
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
BR112019018700A2 (en) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc pharmaceutical compositions and their uses
WO2019169113A1 (en) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
BR112021009832A2 (en) 2018-11-21 2021-08-17 Case Western Reserve University compositions and methods of modulating short-chain dehydrogenase activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP150098A0 (en) * 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
HUP0301833A3 (en) * 2000-07-19 2005-12-28 Bristol Myers Squibb Pharma Co Crf2 ligands in combination therapy
US6437093B1 (en) * 2000-11-28 2002-08-20 Milkhaus Laboratory, Inc. Methods of treatment comprising administration of Substance P
US7439264B2 (en) * 2002-02-08 2008-10-21 President And Fellows Of Harvard College Therapeutic compounds
EP1809104A4 (en) * 2004-09-23 2009-04-29 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONG X.G. ET AL.: "Alterations in the substance P-induced anti-nociception in the central nervous system of rats after morphine tolerance", NEUROSCIENCE LETTERS, vol. 381, no. 1-2, 10 June 2005 (2005-06-10), pages 47 - 50, XP004881632 *
KOOB ET AL., SCIENCE, vol. 278, 3 October 1997 (1997-10-03), pages 52 - 57, XP008130215 *
NESTLER E.J. ET AL.: "MOLECULAR AND CELLULAR BASIS OF ADDICTION", SCIENCE, vol. 278, 3 October 1997 (1997-10-03), pages 58 - 63, XP008037785 *
See also references of EP2001495A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Also Published As

Publication number Publication date
AU2007221135A1 (en) 2007-09-07
JP2009528289A (en) 2009-08-06
EP2001495A4 (en) 2010-12-08
CA2643802A1 (en) 2007-09-07
EP2001495A2 (en) 2008-12-17
WO2007100775A2 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2007100775A3 (en) Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006034343A3 (en) methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007130865A3 (en) Disaster management using an enhanced syndication platform
WO2006128692A3 (en) 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
WO2008009415A3 (en) 4-heteroaryl-substituted 1-aminocyclohexane-1- and cyclohexene-1-derivatives having effects on the opiod receptor system
WO2007130547A3 (en) Remote module syndication system and method
WO2009032737A3 (en) Systems and methods for delivering medication
WO2007084793A3 (en) System and method for generating and delivering personalized content
WO2009063325A3 (en) Methods and systems for treating illnesses
EP2389897A3 (en) Circulatory valve, system and method
WO2006037016A3 (en) Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP2349406A4 (en) Automatic control system and method for the control of anesthesia
WO2006084164A8 (en) Gastric retention and controlled release delivery system
WO2008070269A3 (en) Methods, software and systems for imaging
IL192168A0 (en) System and methods for initiating, maintaining, and delivering personalized information by communication server
WO2008125999A3 (en) Controlled activation of function
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2006127429A3 (en) Selectively sharing screen data
WO2006081279A3 (en) Control of drug release by transient modification of local microenvironments
WO2006002275A3 (en) Catheters incorporating valves and permeable membranes
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
WO2006058059A3 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
EP1808784A3 (en) Method of creating symbolic link capable of being compatible with file system, and method and apparatus for accessing file or directory by using symbolic link
WO2007112366A3 (en) Animal product enrichment using resveratrol
WO2007072992A3 (en) Solid preparation containing an insulin sensitizer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008556468

Country of ref document: JP

Ref document number: 2643802

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007221135

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3610/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007221135

Country of ref document: AU

Date of ref document: 20070227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007751698

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200780015117.5

Country of ref document: CN